Additional Details
-
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
University of Michigan HospitalAnn Arbor MI. 48109 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Baylor College of MedicineHouston TX. 77030 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Piedmont Pulmonary and Sleep Medicine BuckheadAtlanta GA. 30309-1740 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Dr Anil Dhar Professional Medicine CorporationWindsor ON. N8X 5A6 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Northwestern Medicine - Northwestern Medicine GlenGlenview IL. 60026-8039 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
McGovern Medical SchoolHouston TX. 77030-1501 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Kelowna Allergy and Respiratory Health ClinicKelowna BC. V1W 1V3 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
University of Kansas Medical CenterKansas City KS. 66160 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Dynamic Drug Advancement Ltd.Ajax ON. L1S 2J5 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
IU Health Ball Memorial Physicians Pulmonary and Critical Care MedicineMuncie IN. 47303-3432 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Central Florida Pulmonary Group, PAOrlando FL. 32803 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Southeastern Research CenterWinston-Salem NC. 27103-4029 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Hannibal Regional Healthcare System HRMG HannibalHannibal MO. 63401-6890 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Coastal Pulmonary and Critical Care PLCSaint Petersburg FL. 33704-2733 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Renstar Medical ResearchOcala FL. 34470 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
University of Alabama at BirminghamBirmingham AL. 35233 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
El Paso Pulmonary Association Elligo PPDSEl Paso TX. 79902-1124 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Temple UniversityPhiladelphia PA. 19140 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
University of Iowa Hospitals and ClinicsIowa City IA. 52242 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
University of Texas Health Science Center at Houston (UT Health)Houston TX. 77030